Compare Cipher Mining Inc (CIFR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cipher Mining Inc vs Recursion Pharmaceuticals Inc — how do they compare? Cipher Mining Inc trades at $17.86 (market cap $7.14B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Cipher Mining Inc is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap, and Cipher Mining Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CIFR | RXRX | |
|---|---|---|
Market Cap | $7.14B | $1.81B |
Sector | Basic Materials | Health |
52-Week High | $29.18 | $6.79 |
52-Week Low | $4.72 | $2.84 |
Enterprise Value | $11.90B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIFR trades at $18.35, up 12.37% in the last 24 hours, but remains in a bearish technical trend. The company reported a Q2 2026 loss of $0.65 per share, missing estimates, with revenue declining and net losses widening. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target, citing progress in its transition to AI data center operations and accelerated project deliveries.
The outlook hinges on successful execution of its AI infrastructure pivot, offering significant upside if targets are met, but high execution risks and persistent losses pose substantial threats to shareholder value. Investors face volatility amid the business model transition.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
